AstraZeneca PLC [NASDAQ: AZN] price plunged by -0.69 percent to reach at -$0.4. The company report on July 23, 2021 that BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older.
BYDUREON BCise (exenatide extended-release) is the first once-weekly GLP-1 RA treatment option for pediatric patients with type 2 diabetes in the US.
AstraZeneca’s BYDUREON BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise.
A sum of 7172400 shares traded at recent session while its average daily volume was at 10.80M shares. AstraZeneca PLC shares reached a high of $57.67 and dropped to a low of $57.125 until finishing in the latest session at $57.24.
The one-year AZN stock forecast points to a potential upside of 10.0. The average equity rating for AZN stock is currently 1.50, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on AstraZeneca PLC [AZN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $63.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Argus have made an estimate for AstraZeneca PLC shares, keeping their opinion on the stock as Hold, with their previous recommendation back on April 12, 2021. The new note on the price target was released on March 16, 2021, representing the official price target for AstraZeneca PLC stock.
The Average True Range (ATR) for AstraZeneca PLC is set at 1.00, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 6.03. The Price to Book ratio for the last quarter was 9.59, with the Price to Cash per share for the same quarter was set at 5.02. Price to Free Cash Flow for AZN in the course of the last twelve months was 104.58 with Quick ratio for the last quarter at 1.00.
AZN Stock Performance Analysis:
AstraZeneca PLC [AZN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.70. With this latest performance, AZN shares dropped by -4.44% in over the last four-week period, additionally plugging by 13.12% over the last 6 months – not to mention a drop of -1.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 45.25, with the RSI for the last a single of trading hit 43.79, and the three-weeks RSI is set at 47.60 for AstraZeneca PLC [AZN]. The present Moving Average for the last 50 days of trading for this stock 58.12, while it was recorded at 57.19 for the last single week of trading, and 53.25 for the last 200 days.
Insight into AstraZeneca PLC Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and AstraZeneca PLC [AZN] shares currently have an operating margin of +16.98 and a Gross Margin at +74.01. AstraZeneca PLC’s Net Margin is presently recorded at +11.58.
Return on Total Capital for AZN is now 14.29, given the latest momentum, and Return on Invested Capital for the company is 10.66. Return on Equity for this stock inclined to 23.36, with Return on Assets sitting at 5.24. When it comes to the capital structure of this company, AstraZeneca PLC [AZN] has a Total Debt to Total Equity ratio set at 130.46. Additionally, AZN Total Debt to Total Capital is recorded at 56.61, with Total Debt to Total Assets ending up at 30.54. Long-Term Debt to Equity for the company is recorded at 115.18, with the Long-Term Debt to Total Capital now at 49.98.
Reflecting on the efficiency of the workforce at the company, AstraZeneca PLC [AZN] managed to generate an average of $32,750 per employee. Receivables Turnover for the company is 5.35 with a Total Asset Turnover recorded at a value of 0.45.AstraZeneca PLC’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.20.
AZN Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AstraZeneca PLC go to 20.20%.
AstraZeneca PLC [AZN] Insider Position Details
There are presently around $46,929 million, or 14.30% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 59,730,253, which is approximately 173.24% of the company’s market cap and around 0.50% of the total institutional ownership; BLACKROCK INC., holding 51,092,047 shares of the stock with an approximate value of $2.92 billion in AZN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $2.86 billion in AZN stock with ownership of nearly -0.391% of the company’s market capitalization.
Positions in AstraZeneca PLC stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 507 institutional holders increased their position in AstraZeneca PLC [NASDAQ:AZN] by around 154,072,293 shares. Additionally, 607 investors decreased positions by around 138,045,171 shares, while 183 investors held positions by with 527,754,477 shares. The mentioned changes placed institutional holdings at 819,871,941 shares, according to the latest SEC report filing. AZN stock had 110 new institutional investments in for a total of 20,783,415 shares, while 134 institutional investors sold positions of 10,336,358 shares during the same period.